Tolmetin 400mg Rx
Generic Name and Formulations:
Tolmetin sodium 400mg; caps; contains sodium 36mg/cap.
Various generic manufacturers
Indications for Tolmetin 400mg:
Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Treatment of acute flares and the long-term management of the chronic disease. Treatment of juvenile rheumatoid arthritis.
Initially 400mg 3 times daily. Maintenance: 600–1800mg daily in divided doses; max 1800mg/day.
<2yrs: not recommended. ≥2yrs: Initially 20mg/kg/day in divided doses (3–4 times daily). Maintenance: usual dose range: 15–30mg/kg/day; max 30mg/kg/day.
Aspirin allergy. Coronary artery bypass graft surgery.
Advanced renal disease: not recommended. Hypertension; monitor. CHF. Edema. Asthma. History of ulcer disease or GI bleeding. Bleeding disorders. Dehydration. Monitor blood, hepatic, and renal function in chronic use. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat. C: <30 weeks gestation; Cat. D: ≥30 weeks gestation: avoid). Nursing mothers: not recommended.
Avoid aspirin. May antagonize ACE inhibitors, diuretics. Increased risk of GI bleed with oral corticosteroids, anticoagulants (monitor), alcohol, smoking. Methotrexate excretion reduced. Increases lithium levels.
GI upset, abdominal pain, dyspepsia, flatulence, headache, asthenia, elevated BP, edema, dizziness, weight gain, weight loss; rash (discontinue if occurs), GI ulcer/bleed, elevated liver enzymes (discontinue if hepatotoxicity develops), blood dyscrasias, renal papillary necrosis. See literature re: risk of cardiovascular events.
Formerly known under the brand name Tolectin DS.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally